Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2009 Sep 4.
Published in final edited form as: Clin Transl Oncol. 2008 Nov;10(11):726–738. doi: 10.1007/s12094-008-0279-5

Identification of the Rock-dependent transcriptome in rodent fibroblasts

Inmaculada M Berenjeno 1, Xosé R Bustelo 1,
PMCID: PMC2737644  NIHMSID: NIHMS111266  PMID: 19015069

Abstract

Rock proteins are Rho GTPase-dependent serine/threonine kinases with crucial roles in F-actin dynamics and cell transformation. By analogy with other protein kinase families, it can be assumed that Rock proteins act, at least in part, through the regulation of gene expression events. However, with the exception of some singular transcriptional targets recently identified, the actual impact of these kinases on the overall cell transcriptome remains unknown. To address this issue, we have used a microarray approach to compare the transcriptomes of exponentially growing NIH3T3 cells that had been untreated or treated with Y27632, a well known specific inhibitor for Rock kinase activity. We show here that the Rock pathway promotes a weak impact on the fibroblast transcriptome, since its inhibition only results in changes in the expression of 2.3% of all the genes surveyed in the microarrays. Most Y27632-dependent genes are downregulated at moderate levels, indicating that the Rock pathway predominantly induces the upregulation of transcriptionally active genes. Although functionally diverse, a common functional leitmotiv of Y27632-dependent genes is the implication of their protein products in cytoskeletal-dependent processes. Taken together, these results indicate that Rock proteins can modify cytoskeletal dynamics by acting at post-transcriptional and transcriptional levels. In addition, they suggest that the main target of these serine/threonine kinases is the phosphoproteome and not the transcriptome.

Keywords: Rock, Rho/Rac GTPases, Microarray, Gene expression, Transcription, Cytoskeleton

Introduction

The Rho/Rac family is a large group of GTP-binding proteins specialised in the regulation of a wide spectrum of cellular functions such as cytoskeletal organisation, cell proliferation, vesicle trafficking and cytokinesis [16]. Rho/Rac proteins are regulated by extracellular stimulus-dependent changes in their bound guanosine nucleotides. In non-stimulated cells, these proteins are bound to GDP molecules and in an inactive conformation [1, 7]. In addition, they remain sequestered in the cytosol due to their interaction with Rho GDP dissociation inhibitors (RhoGDIs) [1, 8, 9]. In stimulated cells, these proteins are released from RhoGDIs, translocate from the cytosol to cellular membranes and undergo the exchange of GDP by GTP. This exchange of nucleotides promotes a conformational change in the GTPase switch regions that, in turn, allows the binding of downstream effectors [1]. This activation step, as well as its subsequent inactivation by hydrolysis of the bound GTP molecules, is catalysed by guanosine nucleotide exchange factors and GTPase activating proteins, respectively [10, 11]. According to structural criteria, Rho/Rac proteins can be subdivided in Rho (RhoA, RhoB, RhoC), Rac (Rac1, Rac2, Rac3, RhoG) and Cdc42 (Cdc42, TTF) subfamilies [1]. Within the Rho subfamily, RhoA is perhaps the best characterised in terms of three-dimensional structure, effectors and its participation in normal and pathological-related biological responses [1, 1215].

The elucidation of the regulation and function of RhoA effectors is important to understanding the intracellular pathways that control RhoA-dependent cellular, physiological and pathological responses. Two of the main RhoA effectors are the highly related serine/threonine kinases RockI (also known as Rokβ and p160Rock) and RockII (also referred to as both Rokα and Rho kinase) [16, 17]. These proteins become activated during signal transduction by the binding to Rho subfamily members [16, 17] and/or second messengers such as arachidonic acid [18] and sphingo-sylphosphorylcholine [19]. Their activities are also subjected to negative regulation by specific subsets of GTPases (RhoE, Gem, Rad) [20, 21] and cell cycle inhibitors (p21Cip1) [22].

Rock proteins induce intracellular pathways that mediate the formation of stress fibres and focal adhesions, thereby participating in cell-to-cell and cell-to-substratum adhesion, cell migration and motility, phagocytosis and neurite retraction [16, 17]. They also work in cell division and cytokinesis processes by regulating centrosomal functions and actomyosin ring contraction, respectively [16, 17]. Deregulated signalling outputs from these kinases appear to be important for some pathologies, such as hypertension, Alzheimer’s disease and cancer [12, 1417]. Demonstrating the role of these proteins in these diseases, it has been shown that the use of chemical inhibitors for Rock proteins alleviates cardiovascular pathologies such as pulmonary hypertension, vasospasms and angina pectoris [14, 16, 17]. Rock inhibitors also block tumorigenesis in vitro [23] and appear to be potentially useful for the treatment of other medical conditions including Alzheimer’s disease, stroke and neuropathic pain [17].

Several Rock downstream targets have been identified, including regulators of the F-actin cytoskeleton (myosin light chain (MLC), the MLC phosphatase, Lim kinases 1 and 2), intermediate filament components (vimentin, glial fibrillary acidic protein and neurofilaments) and microtubule-associated proteins (Tau, microtubule-associated protein 2) [16, 17]. Whereas the phosphorylation of MLC and its phosphatase by Rock proteins promotes the formation of F-actin fibres, the phosphorylation of other protein classes appears to induce neurofilament disassembly and to halt microtubule polymerisation. Thus, the phosphoproteome induced by Rock proteins is fully consistent with the assigned roles of these proteins in cell migration and morphology [16, 17].

Similar to other serine/threonine kinases involved in signal transduction (i.e., Erk, p38MAPK), it is possible that Rock could also promote the long-term regulation of gene expression. Consistent with this view, it has been shown that Rock activity is important for the stimulation of c-Myc by the constitutively active, oncogenic version of RhoA (Q63L mutant) [24, 25] and for the expression of a small subset of the transcriptome of NIH3T3 cells transformed by the chronic expression of the rhoA oncogene [24]. Other studies have also shown that the expression of specific RhoAQ63L-dependent genes is abrogated upon inhibition of the Rock pathway [26, 27]. In the present study, we aimed at expanding these results to non-transformed fibroblasts. To this end, we used microarray technology to assess the effect of Y27632, a chemical inhibitor commonly used to block Rock kinase activity [28], in the transcriptome of exponentially growing NIH3T3 cells. This cell line has been widely utilised before for the characterisation of the biological properties of both Rho and Rock proteins. Previous observations by us and others have shown that Y27632 treatments inhibit several Rock-dependent responses in this cell line, including MLC phosphorylation and stress fibre formation [23, 24]. We report here the results obtained from this research avenue.

Materials and methods

Cell lines

Murine NIH3T3 cells were grown under standard temperature/CO2 conditions in Dulbecco’s modified Eagle’s medium supplemented with 1% L-glutamine, 1% penicillin/streptomycin and 10% calf serum. All tissue culture reagents were obtained from Invitrogen. When appropriate, cells were treated for 24 h with 10 µM Y27632 (Cal-biochem) to inhibit endogenous Rock proteins. RhoA-transformed cells have been described before [24]. To confirm the effectiveness of Rock inactivation in this experimental setting, parallel cultures of NIH3T3 and RhoA-transformed cells were analysed by immunoblot and immunofluorescence techniques to corroborate the expected inhibition of the phosphorylation of the myosin light chain and the disassembly of stress F-actin fibres in Y27632-treated cells, as indicated and shown before [24].

Microarray experiments and data analysis

Microarray analyses were performed using RNAs obtained from seven and five independent experiments of untreated and Y27632-treated NIH3T3 cells, respectively. In each independent experiment, three 10-cm diameter plates containing exponentially growing cultures were used to generate the total RNA used in the microarray studies. To this end, cultured cells were washed with phosphate-buffered saline solution and total cellular RNAs isolated using the RNeasy kit (Qiagen) according to the supplier’s specifications. The quantity and quality of the total RNAs obtained were determined using 6000 Nano Chips (Agilent Technologies). Total RNA samples (4 µg) were then processed for hybridisation on MGU75Av2 microarrays (Affymetrix) using standard Affymetrix protocols at the CIC Genomics and Proteomics Facility. Normalisation, filtering and analysis of the raw data obtained from microarrays were carried out with the Bioconductor software (www.bioconductor.com) using the ReadAffy package and the RMA application. We considered a gene to be differentially expressed when exhibiting a signal ≥100 and its fold change respect to the levels of expression of untreated NIH3T3 cells was ≥±1.5 and with p values ≤0.01. Statistical analyses were performed using F-statistics.

For the graphical presentation of microarray data, we performed hierarchical clustering analysis using the WP-GA average-linkage and the standard correlation similarity metric method with the J-Express application. Functional annotation of gene functions was performed manually using internet-available databases such as those maintained by the NCBI (www.ncbi.nlm.nih.gov/sites/entrez?db=omim) and the Weizman Institute of Science (Rehovot, Israel; www.genecards.org). The identification of interactive networks of proteins and common functions was done using the Ingenuity Pathways Analysis program, a web-delivered application that enables discovery, visualisation and exploration of biological interaction networks and biological processes (www.ingenuity.com) [29]. In this case, we considered a network as significant when it fulfilled the following criteria: (i) a minimal score of 15; (ii) at least 10 proteins participating in direct, functional interactions inside the network. In addition, and to reinforce the strength of the functional relationships, we only took into consideration direct, not indirect, relationships among the network components. Bioinformatically identified networks were edited manually to sieve out proteins that, according to published data, did not have a coherent or well defined functional relationship with the other network components.

The comparison of transcriptomes between Y27632-treated non-transformed and RhoAQ63L-transformed NIH3T3 cells was done using the previously published data on the RhoAQ63L-dependent transcriptome [24].

Real-time quantitative RT-PCR

Exponentially growing cells treated and non-treated with Y27632 were lysed and total RNA extracted using the RNAeasy kit (Qiagen). RNAs were quantified by loading aliquots into 6000 Nano Chips. Quantitative polynucleotide chain reactions were performed using the Quanti-Tect SYBR Green RT-PCR kit (Qiagen). 18S rRNA primers were used as controls for both loading and quantitation of relative expression levels of the genes tested. Amplifications were performed using the iCycler machine (Bio-Rad). Raw data were analysed using the iCycler iQ Optical System software (version 3.0a, Bio-Rad). In other cases, quantitative RT-PCR experiments were conducted using a microfluidic card (Applied Biosystems) service available at the Program for Genomics, Proteomics and Bioinformatics of the Spanish Network of Cancer Groups.

Results and discussion

We made use of Affymetrix microarray technology to identify the transcriptomal changes induced by culturing exponentially growing NIH3T3 cells with the Rock inhibitor Y27632 for 24 h. The reason for selecting this time point was two-fold. On the one hand, it ensured effective Rock inhibition, since the dephosphorylation of MLC is detected already 6 h after addition of Y27632 and remains at low levels thereafter [24]. On the other hand, this early time point allowed us to select for primary Rock transcriptional targets rather than detecting secondary transcriptomal changes derived from the deregulation of the expression of putative Rock-dependent transcriptional factors. We also cultured cells in the presence of serum and under non-confluent conditions (approx. 70% confluency) to avoid the activation of strong genetic programs related to serum withdrawal or contact inhibition that may obscure the detection of the Rock-dependent transcriptome [30]. In addition, we isolated total RNAs from seven (in the case of NIH3T3 cells) and five (in the case of Y27632-treated cells) independent cell cultures in order to make a robust statistical treatment of the data generated possible. Total RNAs samples obtained under those conditions were converted into biotinylated-cRNA probes and hybridised independently to Affymetrix Genechip MG U74Av2 arrays, thus allowing the monitoring of the expression status of ≈12,500 mouse genes.

The results from these microarray experiments indicated that the chemical inhibition of Rock led to changes in approximately 2.3% (289 genes) of all genes probed in the arrays (Fig. 1A, B and Table 1). Interestingly, these changes involved mostly the downregulation of transcriptionally active genes (76.1% of all responsive genes), indicating that Rock activity is required primarily to maintain transcription from specific gene subsets in mouse fibroblasts. Instead, the inhibition of Rock determined the activation of a much smaller group of 69 genes. To confirm the microarray results, the expression of seven of the upregulated and ten of the downregulated genes was re-evaluated using real-time quantitative RT-PCR analysis. These analyses confirmed that these 17 genes were indeed Rock-dependent (Fig. 2). Interestingly, we also detected genes identified as Rock targets such as cyr61, c-myc and cyclin D1 [24, 26, 27], further supporting the validity of our microarray data.

Fig. 1.

Fig. 1

Transcriptomal changes induced by Y27632 in exponentially growing NIH3T3 cells. A Hierarchical cluster diagram of the 289 genes whose expression levels changed in Y27632-treated cells. Each column represents one experiment and each row a gene. Varying levels of expression are represented on a scale from dark blue (lowest expression) to dark red (highest expression). Note that expression values are represented as signal log ratio numbers (SLR) and that, therefore, the total fold change value is obtained from 2SLR. The experiment number is shown at the top of each column. B Gene graphs showing the induced (red) and repressed (blue) genes in Y27632-treated cells. In each category, the expression values of all deregulated genes are represented as SLR (considering that fold change is 2SLR; y-axis) obtained in each experimental sample (x-axis). The total number of upregulated and downregulated genes in each category is indicated on the right of each panel. C Histogram showing the number of up- (red) and downregulated (blue) genes with a given expression fold change value in Y27632-treated cells

Table 1.

List of genes whose expression is upregulated or downregulated by Y27632 in NIH3T3 cellsa

Function Locus ID Gene Description Changeb p valuec
Extracellular
  Cell adhesion 12825 Col3a1 Procollagen, type III, alpha 1 0.58 0.0017
12832 Col5a2 Procollagen, type V, alpha 2 0.55 0.0001
13003 Cspg2 Chondroitin sulfate proteoglycan 2 1.52 <1.00E-04
16007 Cyr61 Cysteine-rich protein 61 0.26 0.0001
16779 Lamb2 Laminin, beta 2 0.52 0.0014
17313 Mglap Matrix gamma-carboxyglutamate protein 0.53 <1.00E-04
17395 Mmp9 Matrix metalloproteinase 9 1.5 <1.00E-04
114249 Npnt Mus musculus transcribed sequences 0.63 0.0001
18787 Serpine1 Serine (or cysteine) proteinase inhibitor 1 0.61 0.0074
20720 Serpine2 Serine (or cysteine) proteinase inhibitor, 2 0.38 0.0001
20692 Sparc Secreted acidic cysteine rich glycoprotein 0.41 <1.00E-04
13602 Sparcl1 SPARC-like 1 1.54 0.0095
21810 Tgfbi Transforming growth factor beta induced 1.57 <1.00E-04
  Immune response 12266 C3 Complement component 3 4.55 <1.00E-04
19288 Ptx3 Pentaxin related gene 0.21 <1.00E-04
20568 Slpi Secretory leukocyte protease inhibitor 2.39 <1.00E-04
20210 Saa3 Serum amyloid A3 1.89 <1.00E-04
  Ion transport 12870 Cp Ceruloplasmin 4.77 <1.00E-04
  Ligand 14824 Grn Granulin 0.66 0.0039
23893 Grem2 Gremlin 2 homolog 1.76 0.001
20750 Spp1 Secreted phosphoprotein 1 1.82 0.0017
18812 Plf2 Proliferin 2 7.7 <1.00E-04
20311 Cxcl5 Chemokine (C-X-C motif) ligand 5 8.83 <1.00E-04
11535 Adm Adrenomedullin 0.47 <1.00E-04
13642q Efnb2 Ephrin B2 0.61 0.0068
20306 Ccl7 Chemokine (C-C motif) ligand 7 5 <1.00E-04
14825 Cxcl1 Chemokine (C-X-C motif) ligand 1 5.56 <1.00E-04
20296 Ccl2 Chemokine (C-C motif) ligand 2 8.34 <1.00E-04
26421 Mrpplf3 Proliferin 3 14.29 <1.00E-04
21825 Thbs1 Thrombospondin 1 0.21 <1.00E-04
  Other 14118 Fbn1 Fibrillin 1 0.65 0.0064
50530 Mfap5 Microfibrillar associated protein 5 0.5 0.0023
18451 P4ha1 Procollagen-proline, 2-oxoglutarate 4-dioxygenase a 1 0.64 <1.00E-04
14827 Pdia3 Protein disulfide isomerase associated 3 0.48 <1.00E-04
  Receptor activity 12931 Crlf1 Cytokine receptor-like factor 1 1.76 0.0004
  Growth factor 12977 Csf1 Colony stimulating factor 1 0.61 <1.00E-04
14205 Figf C-Fos induced growth factor 0.27 0.0002
18295 Ogn Osteoglycin 0.22 <1.00E-04
19242 Ptn Pleiotrophin 0.31 0.0015
Membrane
  Cell adhesion 12558 Cdh2 Cadherin 2 0.47 <1.00E-04
16403 Itga6 Integrin alpha 6 0.63 0.0003
  Membrane/cell adhesion 20320 Sdfr1 Stromal cell derived factor receptor 1 0.63 0.0004
  Channel-transporter 11826 Aqp1 Aquaporin 1 2.77 <1.00E-04
14726 Gp38 Glycoprotein 38 0.57 0.0001
16497 Kcnab1 Potassium voltage-gated channel beta member 1 0.66 0.0011
20514 Slc1a7 Solute carrier family 1, member 7 0.45 0.0001
67760 Slc38a2 Solute carrier family 38, member 2 0.52 0.0004
22334 Vdac2 Voltage-dependent anion channel 2 0.57 <1.00E-04
  Immune response 15040 H2-T23 Histocompatibility 2, T region locus 23 1.86 0.0008
17069 Ly6e Lymphocyte antigen 6 complex, locus E 1.57 <1.00E-04
  Receptor activity 11609 Agtr2 Angiotensin II receptor, type 2 0.43 0.0026
14062 F2r Coagulation factor II (thrombin) receptor 0.64 <1.00E-04
20321 Frrs1 Ferric-chelate reductase 1 0.6 0.0003
83924 Gpr137b G protein-coupled receptor 137B 2.39 <1.00E-04
16412 Itgb1 Integrin beta 1 0.65 0.0003
16948 Lox Lysyl oxidase 0.66 0.0003
16974 Lrp6 Low density lipoprotein receptor-related protein 6 0.64 0.0012
319900 Npr3 Natriuretic peptide receptor 3 0.33 0.0011
18186 Nrp Neuropilin 0.4 <1.00E-04
19220 Ptgfr Prostaglandin F receptor 2.44 <1.00E-04
21824 Thbd Thrombomodulin 0.47 0.0001
18383 Tnfrsf11b Tumour necrosis factor receptor superfamily 1b 1.57 0.0007
21937 Tnfrsf1a Tumour necrosis factor receptor superfamily 1a 1.52 0.0015
14102 Tnfrsf6 Tumour necrosis factor receptor superfamily 6 1.57 <1.00E-04
  Signal transducer activity 11487 Adam10 A disintegrin and metalloprotease domain 10 0.62 0.0004
17118 Marcks Myristoylated alanine rich protein kinase C substrate 0.42 0.0001
18858 Pmp22 Peripheral myelin protein 0.64 0.0007
20338 Sel1h Sel1 1 homolog 0.52 <1.00E-04
  Other 11502 Adam9 A disintegrin and metalloproteinase domain 9 0.45 <1.00E-04
319434 Amot Angiomotin 0.6
13244 Degs Degenerative spermatocyte homologue 0.57 <1.00E-04
53872 Gpiap1 GPI-anchored membrane protein 1 0.58 0.0005
20014 Rpn2 Ribophorin II 0.64 0.0033
20324 Sdpr Serum deprivation response 0.37 <1.00E-04
20908 Stx3 Syntaxin 3 0.53 0.0014
21838 Thy1 Thymus cell antigen 1 theta 0.5 <1.00E-04
232086 TM6P1 Fasting-inducible integral membrane protein TM6P1 0.65 0.0094
  Nuclear membrane 67154 Mtdh Metadherin 0.65 0.0063
Cytoskeleton 226251 Ablim1 Actin-binding LIM protein 1 0.56 0.0023
26357 Abcg2 ATP-binding cassette, sub-family G2 0.65 0.0023
11475 Acta2 Actin, alpha 2, smooth muscle 0.18 <1.00E-04
11464 Actc1 Actin, alpha, cardiac 0.57 <1.00E-04
109711 Actn1 Actinin alpha 1 0.54 0.0008
12798 Cnn2 Calponin 2 0.49 <1.00E-04
13007 Csrp1 Cysteine and glycine-rich protein 1 0.58 0.0001
13860 Eps8 Epidermal growth factor receptor pathway substrate 8 0.56 0.0001
14086 Fscn1 Fascin homologue 1 0.55 <1.00E-04
56486 Gabarap Gamma-aminobutyric acid receptor associated protein 0.66 0.0004
19348 Kif20a Kinesin family member 20A 1.64 0.0049
16571 Kif4 Kinesin family member 4 1.89 0.007
16573 Kif5b Kinesin family member 5B 0.57 0.0014
65970 Lima1 LIM domain and actin binding 1 0.61 0.0009
11426 Macf1 Microtubule-actin crosslinking factor 1 0.64 < 1.00E-04
17886 Myh9 Myosin heavy chain IX 0.49 <1.00E-04
17909 Myo10 Myosin X 0.6 0.0002
83431 Ndel1 Nuclear distribution gene E-like homolog 1 0.63 0.0001
218952 Plekhc1 Pleckstrin homology domain containing, family C1 0.56 0.0001
20740 Spna2 Spectrin alpha 2 0.49 0.0004
20742 Spnb2 Spectrin beta 2 0.55 0.0005
104027 Synpo Synaptopodin 0.59 0.0028
21345 Tagln Transgelin 0.26 <1.00E-04
21894 Tln Talin 0.63 <1.00E-04
19241 Tmsb4x Thymosin, beta 4, X chromosome 0.51 <1.00E-04
22003 Tpm1 Tropomyosin 1, alpha 0.59 <1.00E-04
22330 Vcl Vinculin 0.44 <1.00E-04
Intracellular
Signal transducer activity 12388 Catns Catenin src 0.6 0.0035
83397 Akap12 A kinase anchor protein 12 0.38 0.0001
54519 Apbb1ip Amyloid beta precursor-binding 1 interacting protein 0.43 <1.00E-04
80837 Arhj Ras homologue gene family J 0.64 0.0046
19252 Dusp1 Dual specificity phosphatase 1 0.6 0.0002
67603 Dusp6 Dual specificity phosphatase 6 0.24 <1.00E-04
74155 Errfi1 ERBB receptor feedback inhibitor 1 0.51 0.0027
212398 Frat2 Frequently rearranged in T-cell lymphomas 2 1.57 <1.00E-04
16413 Itgb1bp1 Integrin beta 1 binding protein 1 0.6 <1.00E-04
50523 Lats2 Large tumour suppressor 2 0.52 0.0001
26410 Map3k8 Mitogen activated protein kinase kinase kinase 8 1.7 <1.00E-04
18647 Pftk1 PFTAIRE protein kinase 1 0.63 <1.00E-04
18708 Pik3r1 P85 alpha 2.28 <1.00E-04
19046 Ppp1cb Protein phosphatase 1, catalytic subunit, beta isoform 0.47 0.0013
56044 Rala V-ral simian leukaemia viral oncogene homologue A 0.63 0.001
218397 Rasa1 RAS p21 protein activator 1 0.63 0.0009
56437 Rrad Ras-related associated with diabetes 1.52 <1.00E-04
16765 Stmn1 Stathmin 1 1.82 0.0077
21353 Tank TRAF NF-kappa B activator 0.48 0.0001
68842 Tulp4 Tubby like protein 4 0.65 0.0012
59043 Wsb2 WD-40-repeat-containing protein with a SOCS box 0.52 <1.00E-04
Protein biosynthesis 16341 Eif3s6 Eukaryotic translation initiation factor 3, subunit 6 0.58 0.0026
107508 Eprs Glutamyl-prolyl-trna synthetase 0.66 0.0052
23874 Farsl Phenylalanine-tRNA synthetase-like 0.65 0.003
Protein folding and modification 12469 Cct8 Chaperonin subunit 8 0.64 0.0021
14976 H2-Ke2 H2-K region expressed gene 2 1.52 0.0015
14828 Hspa5 Heat shock 70 kDa protein 5 0.63 0.0011
15481 Hspa8 Heat shock protein 8 0.59 <1.00E-04
217664 Mgat2 Mannoside acetylglucosaminyltransferase 2 0.61 0.0005
12406 Serpinh1 Serine (or cysteine) proteinase inhibitor, clade H 1 0.66 0.0001
54609 Ubqln2 Ubiquilin 2 0.52 0.0004
Proteolysis and peptidolysis 67526 Apg12l Autophagy 12-like 1.73 0.0004
17035 Lxn Latexin 0.58 0.0069
22194 Ube2e1 Ubiquitin-conjugating enzyme E2E 1 0.52 0.0022
70620 Ube2v2 Ubiquitin-conjugating enzyme E2 variant 2 0.66 0.004
59025 Usp14 Ubiquitin specific protease 14 0.62 0.0025
Heat shock 15505 Hsp105 Heat shock protein 105 0.55 <1.00E-04
15519 Hspca Heat shock protein 1 alpha 0.65 0.0009
Apoptosis 54673 Bif-1 SH3-domain GRB2-like B1 0.58 <1.00E-04
12363 Casp4 Caspase 4, apoptosis-related cysteine protease 1.64 <1.00E-04
114774 Pawr PRKC apoptosis WT1 regulator 0.59 0.0011
Cell cycle 215387 Brrn1 Barren homologue 1.79 0.0086
12442 Ccnb2 Cyclin B2 1.82 0.0003
12443 Ccnd1 Cyclin D1 0.55 <1.00E-04
12453 Ccni Cyclin I 0.54 0.002
12532 Cdc25c Cell division cycle 25 homologue C 1.79 0.0054
12545 Cdc7 Cell division cycle 7 1.5 0.0038
59125 Nek7 NIMA-related expressed kinase 7 0.65 0.0001
30939 Pttg1 Pituitary tumour-transforming 1 2 0.0002
DNA replication and repair 12615 Cenpa Centromere autoantigen A 2 0.0007
69072 Ebna1bp2 EBNA1 binding protein 2 0.6 0.0016
15569 Elavl2 ELAV-like 2 0.62 0.0001
15078 H3f3a H3 histone, family 3A 0.58 0.0011
15364 Hmga2 High mobility group AT-hook 2 0.66 0.0005
15354 Hmgb3 High mobility group box 3 2.18 0.0024
50887 Nsbp1 Nucleosome binding protein 1 1.54 0.0006
21974 Top2b Topoisomerase (DNA) II beta 0.63 0.0003
Regulation of transcription 107503 Atf5 Activating transcription factor 5 0.58 <1.00E-04
12034 Bcap37 Dentatorubral pallidoluysian atrophy 1.58 0.0002
12051 Bcl3 B-cell leukaemia/lymphoma 3 1.59 <1.00E-04
12053 Bcl6 B-cell leukaemia/lymphoma 6 0.61 <1.00E-04
57316 C1d C1d nuclear DNA binding protein 0.64 0.0083
17684 Cited2 Cbp/p300-interacting transactivator 2 0.59 <1.00E-04
107765 Crap Cardiac responsive adriamycin protein 0.35 <1.00E-04
13017 Ctbp2 C-terminal binding protein 2 0.65 0.001
23871 Ets1 E26 avian leukemia oncogene 1 0.61 0.0054
14200 Fhl2 Four and a half LIM domains 2 0.66 <1.00E-04
15904 Idb4 Inhibitor of DNA binding 4 0.57 0.0003
26388 Ifi202b Interferon activated gene 202B 0.52 0.0002
16978 Lrrfip1 Leucine rich repeat interacting protein 1 0.49 <1.00E-04
17869 Myc Myelocytomatosis oncogene 0.54 0.0055
27057 Ncoa4 Nuclear receptor coactivator 4 0.63 0.0001
18028 Nfib Nuclear factor I/B 0.57 0.0031
18035 Nfkbia Nuclear factor of kappa B inhibitor alpha 1.7 <1.00E-04
80859 Nfkbiz Nuclear factor of kappa B inhibitor zeta 2.64 <1.00E-04
353187 Nr1d2 Nuclear receptor subfamily 1, group D, member 2 1.5 0.0001
11819 Nr2f2 Nuclear receptor subfamily 2, group F, member 2 0.5 <1.00E-04
22634 Plagl1 Pleiomorphic adenoma gene-like 1 0.61 0.0093
19664 Rbpsuh Recombining binding protein suppressor of hairless 1.67 <1.00E-04
19698q Relb Avian reticuloendotheliosis viral (v-rel) oncogene B 1.62 <1.00E-04
67155 Smarca2 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subf.a, mem2 0.43 6.00E-04
20677 Sox4 SRY-box containing gene 4 1.79 <1.00E-04
21807 Tgfb1i4 Transforming growth factor beta 1 induced transcript 4 1.57 <1.00E-04
228775 Trib3 Tribbles homologue 3 1.67 <1.00E-04
22160 Twist1 Ubiquitin-conjugating enzyme E2D 3 0.5 <1.00E-04
22433 Xbp1 X-box binding protein 1 0.62 <1.00E-04
RNA metabolism 14007 Cugbp2 CUG triplet repeat,RNA binding protein 2 0.52 0.0004
18569 Pdcd4 Programmed cell death 4 0.63 0.0017
81898 Sf3b1 Splicing factor 3b, subunit 1 0.52 0.0001
20823 Ssb Sjogren syndrome antigen B 0.54 0.0016
12192 Zfp36l1 Zinc finger protein 36, C3H type-like 1 1.73 0.0001
Metabolism
  Lipid metabolism 208715 Hmgcs1 3-Hydroxy-3-methylglutaryl-Coenzyme A synthase 1 0.62 <1.00E-04
16956 Lpl Lipoprotein lipase 0.65 0.0017
67041 Oxct 3-Oxoacid coa transferase 0.66 0.0001
27273 Pdk4 Pyruvate dehydrogenase kinase, isoenzyme 4 0.63 0.0013
18783 Pla2g4a Phospholipase A2, group IVA 0.66 0.0008
66234 Sc4mol Sterol-C4-methyl oxidase-like 0.63 <1.00E-04
235293 Sc5d Sterol-C5-desaturase 0.47 0.0005
20397 Sgpl1 Sphingosine phosphate lyase 1 0.66 0.0004
56442 Tde1l Tumour differentially expressed 2 0.63 0.0001
  Carbohydrate metabolism 15926 Idh1 Isocitrate dehydrogenase 1 (NADP+) 0.64 0.0005
  Nucleic acid-related 104444 Rexo2 RNA exonuclease 2 homologue 0.57 < 1.00E-04
  Electron transporter 70495 Atp6ip2 Atpase, H+ transporting accessory protein 2 0.58 0.0003
11972 Atp6v0d1 Atpase, H+ transporting, V0 subunit D isoform 1 0.59 0.0003
11964 Atp6v1a1 Atpase, H+ transporting, V1 subunit A, isoform 1 0.53 0.0004
11966 Atp6v1b2 Atpase, H+ transporting, V1 subunit B, isoform 2 0.62 0.0013
66335 Atp6v1c1 Atpase, H+ transporting, V1 subunit C, isoform 1 0.63 0.0002
12864 Cox6c Cytochrome c oxidase, subunit vic 0.64 0.0003
13078 Cyp1b1 Cytochrome P450, family 1, subfamily b, polypep. 1 0.53 0.0008
  Glutathione metabolism 14873 Gsto1 Glutathione S-transferase omega 1 0.66 <1.00E-04
  Other 11668 Aldh1a1 Aldehyde dehydrogenase family 1, subfamily A1 0.23 0.001
56332 Amotl2 Angiomotin like 2 0.45 <1.00E-04
14199 Fhl1 Four and a half LIM domains 1 0.62 0.0015
15939 Ier5 Immediate early response 5 0.33 <1.00E-04
17161 Maoa Monoamine oxidase A 0.44 <1.00E-04
19317 Qk Quaking 0.58 0.001
52357 Wwc2 WW, C2 and coiled-coil domain containing 2 0.61 <1.00E-04
Other 11630 Aim1 Absent in melanoma 1 1.52 0.0001
11737 Anp32a Acidic nuclear phosphoprotein 32 family, member A 1.5 <1.00E-04
20239 Atxn2 Ataxin 2 0.66 <1.00E-04
110147 Bat8 HLA-B associated transcript 8 0.65 0.0002
223770 Brd1 Bromodomain containing 1 0.64 0.0005
12512 Cd63 Cd63 antigen 0.66 <1.00E-04
321022 Cdv3 Carnitine deficiency-associated of ventricle 3 0.63 0.0001
13008 Csrp2 Cysteine and glycine-rich protein 2 1.67 0.0001
13025 Ctla2b Cytotoxic T lymphocyte-associated protein 2 beta 0.56 0.0077
14209 Fin14 Fibroblast growth factor inducible 14 0.63 0.0073
17263 Gtl2 GTL2, imprinted maternally expressed mRNA 0.65 0.0028
72568 Lin9 Lin-9 homologue 1.54 0.0025
17184 Matr3 Matrin 3 0.65 0.006
17966 Nbr1 Neighbour of Brca1 gene 1 0.6 <1.00E-04
30877 Ns Nucleostemin 0.61 0.0003
18203 Ntan1 N-terminal Asn amidase 0.59 0.0001
269424 Phf17 PHD finger protein 17 0.6 0.0001
56705 Ranbp9 RAN binding protein 9 0.6 0.0003
26611 Rcn2 Reticulocalbin 2 0.59 0.0012
319714 Rnase4 Ribonuclease, rnase A family 4 0.51 0.0043
20715 Serpina3g Serine (or cysteine) proteinase inhibitor, clade A-3G 1.64 <1.00E-04
94186 Strn3 Striatin, calmodulin binding protein 3 0.52 0.0001
22134 Tgoln1 Trans-Golgi network protein 0.63 0.0005
53612 Vti1b Vesicle transport t-SNARE interactor, 1B homologue 0.61 0.0001
211652 Wwc1 WW, C2 and coiled-coil domain containing 1 0.47 <1.00E-04
53861 Zfp265 Zinc finger protein 265 0.61 0.0055
Transport
  Vesicle transport 16952 Anxa1 Annexin A1 0.34 <1.00E-04
11745 Anxa3 Annexin A3 0.27 <1.00E-04
12389 Cav Caveolin, caveolae protein 0.59 0.0001
13429 Dnm Dynamin 1.62 <1.00E-04
16784 Lamp2 Lysosomal membrane glycoprotein 2 0.62 0.0002
53869 Rab11a RAB11a, member RAS oncogene family 0.63 0.0004
22319 Vamp3 Vesicle-associated membrane protein 3 0.6 0.0036
  Protein-nucleus import 16649 Kpna4 Karyopherin alpha 4 0.53 0.0002
  Protein transport 216363 Rab3ip RAB3A interacting protein 0.65 <1.00E-04
a

Genes have been classified into 19 different functional groups. The locus identification number (Locus ID), the gene symbol (gene) and spelled out designation of each gene are shown. For the sake of simplicity, EST clones with unknown functions have not been included in the list.

b

Fold change in gene expression levels upon a 24-h-long treatment with Y27632.

c

p-values of genes affected in NIH3T3 cells determined with the F-statistic. p-values lower than 1.00E-04 are shown as <1.00E-04

Fig. 2.

Fig. 2

Corroboration of Affymetrix data by quantitative RT-PCR. A, B Expression levels of the indicated up-regulated (A) and downregulated (B) mRNAs by the Y27632 treatment were determined by either microarray (A, grey bars) or quantitative RT-PCR (Q, black bars). Values are expressed as fold change of the appropriate gene with respect to the transcript levels found in untreated NIH3T3 cells

We observed that the Rock-dependent genes were distributed following a Poisson-like distribution when classified in terms of overall fold-change variations (Fig. 1C). Thus, the majority of up- and downregulated genes displayed modest changes (1.5–2.1-fold) when their expression levels were compared between Y27632-treated and untreated NIH3T3 cells. Instead, only a small minority of genes showed fold-change variations outside that interval (Fig. 1C). Upregulated and downregulated genes followed similar trends, although we only observed upregulated loci in the subset of genes displaying variations larger than 6-fold (Fig. 1C). We observed that the genes undergoing the largest upregulation encoded either chemokines (Ccl13, Cxcl6, Ccl7) or secreted factors (Cp and the component 3 of the complement) (Table 1). Instead, the genes with largest repressions encoded for cytoskeletal-related proteins such as actin α2, Ptx3, Thbs1 and Ogn (Table 1).

To establish an overview of the transcriptional changes induced by Rock inhibition, we assigned the 289 identified genes regulated by Y27632 to 19 different functional groups using manual annotation procedures (Fig. 3A, Table 1). This analysis revealed that the main functional groups targeted by the Y27632 include those corresponding to extra-cellular matrix proteins, membrane-localised proteins, cytoskeleton, transcriptional regulation and metabolism. With the exception of the apoptosis and cell cycle-related class, all the other functional groups contain a larger number of downregulated than of upregulated genes. In fact, five of those classes (growth factors, protein biosynthesis, heat shock, metabolism, cytoplasmic/nuclear transport) contain only repressed genes (Fig. 3A, Table 1). Interestingly, the largest percentage of upregulated genes is seen in the immune-related (83%), cell cycle (63%), ligand (58%) and membrane receptor (83%) subclasses (Table 1).

Fig. 3.

Fig. 3

Functional annotation and characterisation of Y27632-dependent genes. A Classification of up- (red) and downregulated (blue) genes by the Y27632 treatment according to general biological functions. BD The molecular networks identified using the Ingenuity database in the Y27632-affected transcriptome. Nodes are colour-coded in red (upregulated) or green (downregulated) according to their fold change values

The main problem with functional annotation is that it groups genes according to functional similarity or relatedness. Due to this, this type of analysis usually oversees other important biological information, such as the interconnectivities established among genes of different functional classes, homogeneous alterations of signal transduction pathways, etc. To surmount this problem, we subjected our microarray data to further bioinformatic characterisation using the Ingenuity program. This web-based software allows the identification of common biological processes and molecular networks because it relates each gene entry with a comprehensive database of known protein–protein, transcriptional or enzymatic relationships available for = 10,000 mammalian proteins [29]. At the level of molecular networks, the analysis of the Y27632-targeted transcriptome using this bioinformatics package indicated changes in the expression of genes whose protein products are involved in integrin and c-Myc function (Fig. 3C,D). The composition of the first network is, however, limited to specific integrin subunits and proximal cytoskeletal components (see below), indicating that the signalling cascades located down-stream of integrins are not touched by the inhibition of the Rock route. The detection of the c-Myc network is of interest, because we have shown before that the overexpression of RhoAQ63L promotes this network whereas the inhibition of Rock downmodulates it in rhoA-transformed cells [24]. A third molecular network contained a larger number of protein constituents (30 in total) (Fig. 3B). This network can be further subdivided into two main branches, one that is loosely related with the Ccl7 and Ccl13 chemokines and one of its repressors (the transcriptional factor Bcl6) and another branch connecting the downmodulation of specific nuclear proteins (Xbp1, Nr2f2) with the repression of the expression of extracellular proteins such as collagen, serpin and a lipoprotein lipase (Lpl). Unlike the other two networks, this third molecular conglomerate does include nuclear, cytosolic, membrane and extracellular-located molecules, suggesting that its targeting by the Rock pathway may have some signalling purpose. To our knowledge, however, this network has not been linked to any established biological process so far. Quantitative RT-PCR experiments demonstrated that the selected elements of these three networks are indeed deregulated upon treatment of NIH3T3 cells with the Rock inhibitor (Fig. 4). At the level of biological processes affected, the bioinformatic analysis indicated that the inactivation of Rock by Y27632 alters, in a statistically significant manner (p≤0.001), genes whose protein products are primarily in charge of cellular functions usually regulated by these serine/threonine kinases such as cellular movement (migration, chemotaxis, transmigration, haptotaxis, invasion, scattering), cell morphology and the extracellular matrix. The products of these genes were also either directly (i.e., c-Myc) or indirectly (rest of genes) linked to cell growth and survival processes. However, this latter functional category probably has poor significance from a biological point of view, because we have not detected a large pool of genes directly activated or repressed in proliferating cells (i.e., proteins directly involved in the cell cycle machinery, replication origins, DNA synthesis, etc.) (Table 1). This is consistent with previous observations by us and others indicating that Y27632 treatments do not significantly alter the proliferation rates of fibroblasts [23, 24]. Based on these results, the only obvious common feature observed among these transcriptomal changes is their relationship, direct or indirect, with integral and regulatory components of cellular components usually regulated by Rock proteins such as F-actin cytoskeleton, microtubules and cell movement-related processes. Consistent with this view, it was observed that cytoskeleton-related proteins (actinin, vinculin, calponin, talin, spectrins, actin itself), cytoskeletal regulators (thy-mosin β4, myosin subunits, integrins, transgelin, catenin, Nap125, dynamin, caveolin) and microtubule-related molecules (Macf1, kinesins) showed up in most of the networks and pathways picked up by the Ingenuity software.

Fig. 4.

Fig. 4

Corroboration of the molecular networks identified in Fig. 3 by quantitative RT-PCR. AC RT-PCR-determined expression levels of selected genes belonging to the molecular networks shown in Fig. 3B (A), 3C (B) and 3D (C). Values are expressed as fold change of the appropriate gene with respect to the transcript levels found in untreated NIH3T3 cells

We have previously shown that the inhibition of Rock in RhoAQ63L-transformed NIH3T3 cells with Y27632 also provokes minor changes in the cell transcriptome of these oncogenically transformed cells [24]. The similarity in the experimental conditions used in that work and in the current study made it possible to compare side by side the effects of Y27632 in transformed and non-transformed cells. This analysis indicated that Y27632 induced larger expression changes in the transcriptome of non-transformed (298 genes) than in RhoAQ63L-transformed (179 genes) cells. Moreover, we have observed that the gene subsets targeted by the Rock inhibitor in the parental and the RhoAQ63L-transformed NIH3T3 cells were significantly different, since these two transcriptomes only show 70 coincident target genes. These shared genes showed the same change pattern and belonged to both the upregulated (17 genes) and downregulated (53 genes) classes. This subset of genes included the c-Myc network detected in the Ingenuity analysis, although this interactive molecular network has a larger number of components in RhoA-transformed cells than in the non-transformed parental cells [this work, 24]. Four additional genes, although targeted by Y27632 in both cell types, showed opposite change patterns in normal and RhoAQ63L-transformed cells. The functional classes deregulated by the Y27632 treatment that displayed more disparity between non-transformed and transformed cells were those related with membrane-located, cell adhesion-related proteins, cell cycle, DNA replication and electron transporter. The classes showing more coincident expression changes encompassed those related to extracellular, cell-adhesion-related functions, extracellular ligands, cytoskeleton, regulation of transcription and proteins with unassigned functions. These data indicate that the impact of the Rock pathway on the transcriptome is always small regardless of whether fibroblasts have normal or exacerbated RhoA activity levels. However, the type of genes targeted by this signalling route is significantly different depending on the transformed status of these cells.

In summary, these results indicate that the Rock pathway has a rather weak impact in the transcriptome of normal fibroblasts. Therefore, they are consistent with the idea that the main signalling purpose of this route is to induce phosphoproteomal rather than transcriptomal changes in the cell. Furthermore, the relative small fold change variations found in the majority of Y27632-targeted genes indicated that the transcriptional action of the Rock pathway relies mainly on modulating the levels of activity of already active genes rather than on turning on previously silent loci or turning off active genes. Interestingly, most Rock-dependent transcriptional targets are downmodulated upon inhibition of Rock activity, indicating that the Rock pathway is oriented fundamentally to the upregulation of genes under exponentially growing conditions. Finally, we have observed that the main transcriptional targets affected by the blockage of Rock activity in fibroblasts are related with processes of cell movement, cell shape and F-actin dynamics. Thus, the post-transcriptional action of Rock proteins on the F-actin cytoskeleton appears to be coordinated, in the long-term, with the modulation at the transcriptional level of genes involved in the regulation of those components of the cell architecture. It will be important in the future to complement these studies with others focused on the cell proteome and phosphoproteome to get a comprehensive view of the effects and impact of Rock function in the biology of the mammalian cells.

Acknowledgements

We wish to thank E. Fermiñán (CIC Genomics and Proteomics Unit) and M. Blázquez for array hybridisations and general technical assistance, respectively. This work was supported by aids to XRB from the Ramón Areces Foundation, the Special Action on Genomics and Proteomics of the Spanish Ministry of Education and Science (GEN2003-20239-C06-01), the US National Cancer Institute/NIH (5R01-CA73735-11), the Spanish Ministry of Education and Science (SAF2006-01789), the Castilla-León Autonomous Government (SA053A05) and the Red Temática de Investigación Co-operativa en Cáncer (RTICC) (RD06/0020/0001, Fondo de Investigaciones Sanitarias (FIS), Carlos III Institute, Spanish Ministry of Health). IMB was supported by a FPU fellowship (FP2000-6489) of the Spanish Ministry of Education and Science and by the US National Cancer Institute. All Spanish funding is co-sponsored by the European Union FEDER programme.

Footnotes

The genomic data of this work are deposited in the NCBI Gene Expression Omnibus database (Accession number: GSE5913).

References

  • 1.Bustelo XR, Sauzeau V, Berenjeno IM. GTP-binding proteins of the Rho/Rac family: regulation, effectors and functions in vivo. Bioessays. 2007 Apr;29:356–370. doi: 10.1002/bies.20558. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Van Aelst L, D'Souza-Schorey C. Rho GTPases and signaling networks. Genes Dev. 1997;11:2295–2322. doi: 10.1101/gad.11.18.2295. [DOI] [PubMed] [Google Scholar]
  • 3.Symons M, Rusk N. Control of vesicular trafficking by Rho GTPases. Curr Biol. 2003;13:R409–R418. doi: 10.1016/s0960-9822(03)00324-5. [DOI] [PubMed] [Google Scholar]
  • 4.Etienne-Manneville S, Hall A. Rho GTPases in cell biology. Nature. 2002;420:629–635. doi: 10.1038/nature01148. [DOI] [PubMed] [Google Scholar]
  • 5.Coleman ML, Marshall CJ, Olson MF. RAS and RHO GTPases in G1-phase cell-cycle regulation. Nat Rev Mol Cell Biol. 2004;5:355–366. doi: 10.1038/nrm1365. [DOI] [PubMed] [Google Scholar]
  • 6.Jaffe AB, Hall A. Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol. 2005;21:247–269. doi: 10.1146/annurev.cellbio.21.020604.150721. [DOI] [PubMed] [Google Scholar]
  • 7.Colicelli J. Human RAS superfamily proteins and related GTPases (250)RE13. 2004 doi: 10.1126/stke.2502004re13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.DerMardirossian C, Bokoch GM. GDIs: central regulatory molecules in Rho GTPase activation. Trends Cell Biol. 2005;15:356–363. doi: 10.1016/j.tcb.2005.05.001. [DOI] [PubMed] [Google Scholar]
  • 9.Dransart E, Olofsson B, Cherfils J. RhoGDIs revisited: novel roles in Rho regulation. Traffic. 2005;6:957–966. doi: 10.1111/j.1600-0854.2005.00335.x. [DOI] [PubMed] [Google Scholar]
  • 10.Rossman KL, Der CJ, Sondek J. GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors. Nat Rev Mol Cell Biol. 2005;6:167–180. doi: 10.1038/nrm1587. [DOI] [PubMed] [Google Scholar]
  • 11.Bos JL, Rehmann H, Wittinghofer A. GEFs and GAPs: critical elements in the control of small G proteins. Cell. 2007;129:865–877. doi: 10.1016/j.cell.2007.05.018. [DOI] [PubMed] [Google Scholar]
  • 12.Benitah SA, Valeron PF, van Aelst L, Marshall CJ, Lacal JC. Rho GTPases in human cancer: an unresolved link to upstream and downstream transcriptional regulation. Biochim Biophys Acta. 2004;1705:121–132. doi: 10.1016/j.bbcan.2004.10.002. [DOI] [PubMed] [Google Scholar]
  • 13.Boettner B, Van Aelst L. The role of Rho GTPases in disease development. Gene. 2002;286:155–174. doi: 10.1016/s0378-1119(02)00426-2. [DOI] [PubMed] [Google Scholar]
  • 14.Budzyn K, Marley PD, Sobey CG. Targeting Rho and Rho-kinase in the treatment of cardiovascular disease. Trends Pharmacol Sci. 2002;27:97–104. doi: 10.1016/j.tips.2005.12.002. [DOI] [PubMed] [Google Scholar]
  • 15.Sahai E, Marshall CJ. RHO-GTPases and cancer. Nat Rev Cancer. 2002;2:133–142. doi: 10.1038/nrc725. [DOI] [PubMed] [Google Scholar]
  • 16.Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour. Nat. Rev. Cell Biol. 2003;4:446–456. doi: 10.1038/nrm1128. [DOI] [PubMed] [Google Scholar]
  • 17.Mueller BK, Mack H, Teusch N. Rho kinase, a promising drug target for neurological disorders. Nat Rev Drug Discov. 2005;4:387–398. doi: 10.1038/nrd1719. [DOI] [PubMed] [Google Scholar]
  • 18.Fu X, Gong MC, Jia T, Somlyo AV, Somlyo AP. The effects of the Rho-kinase inhibitor Y-27632 on arachidonic acid-, GTPgammaS-, and phorbol ester- induced Ca2+-sensitization of smooth muscle. FEBS Lett. 1998;440:183–187. doi: 10.1016/s0014-5793(98)01455-0. [DOI] [PubMed] [Google Scholar]
  • 19.Shirao S, Kashiwagi S, Sato M, et al. Sphingosylphosphorylcholine is a novel messenger for Rho-kinase-mediated Ca2+ sensitization in the bovine cerebral artery: unimportant role for protein kinase C. Circulation research. 2002;91:112–119. doi: 10.1161/01.res.0000026057.13161.42. [DOI] [PubMed] [Google Scholar]
  • 20.Riento K, Guasch RM, Garg R, Jin B, Ridley AJ. RhoE binds to ROCK I and inhibits downstream signaling. Mol Cell Biol. 2003;23:4219–4229. doi: 10.1128/MCB.23.12.4219-4229.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Ward Y, Yap SF, Ravichandran V, Matsumura F, Ito M, Spinelli B, Kelly K. The GTP binding proteins Gem and Rad are negative regulators of the Rho-Rho kinase pathway. J Cell Biol. 2002;157:291–302. doi: 10.1083/jcb.200111026. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Lee S, Helfman DM. Cytoplasmic p21Cip1 is involved in Ras-induced inhibition of the ROCK/LIMK/cofilin pathway. J Biol Chem. 2004;279:1885–1891. doi: 10.1074/jbc.M306968200. [DOI] [PubMed] [Google Scholar]
  • 23.Sahai E, Ishizaki T, Narumiya S, Treisman R. Transformation mediated by RhoA requires activity of ROCK kinases. Curr Biol. 1999;9:136–145. doi: 10.1016/s0960-9822(99)80067-0. [DOI] [PubMed] [Google Scholar]
  • 24.Berenjeno IM, Nunez F, Bustelo XR. Transcriptomal profiling of the cellular transformation induced by Rho subfamily GTPases. Oncogene. 2007;26:4295–4305. doi: 10.1038/sj.onc.1210194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Chiariello M, Marinissen MJ, Gutkind JS. Regulation of c-myc expression by PDGF through Rho GTPases. Nat Cell Biol. 2001;3:580–586. doi: 10.1038/35078555. [DOI] [PubMed] [Google Scholar]
  • 26.Han JS, Macarak E, Rosenbloom J, Chung KC, Chaqour B. Regulation of Cyr61/CCN1 gene expression through RhoA GTPase and p38MAPK signaling pathways. Eur J Biochem. 2003;270:3408–3421. doi: 10.1046/j.1432-1033.2003.03723.x. [DOI] [PubMed] [Google Scholar]
  • 27.Croft DR, Olson MF. The Rho GTPase effector ROCK regulates cyclin A, cyclin D1, and p27Kip1 levels by distinct mechanisms. Mol Cell Biol. 2006;26:4612–4627. doi: 10.1128/MCB.02061-05. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Uehata M, Ishizaki T, Satoh H, et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 1997;389:990–994. doi: 10.1038/40187. [DOI] [PubMed] [Google Scholar]
  • 29.Calvano SE, Xiao W, Richards DR, et al. A network-based analysis of systemic inflammation in humans. Nature. 2005 Oct 13;437(7061):1032–1037. doi: 10.1038/nature03985. [DOI] [PubMed] [Google Scholar]
  • 30.Coller HA, Sang L, Roberts JM. A new description of cellular quiescence. PLoS Biol. 2006;4:e83. doi: 10.1371/journal.pbio.0040083. [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES